Mounting a strategic offense: fighting tumor vasculature with oncolytic viruses
Authors:
- Fernando A. AngaritaFAFernando A. Angarita
- Sergio A. AcunaSASergio A. Acuna
- Kathryn Ottolino-PerryKOKathryn Ottolino-Perry
- Siham ZerhouniSZSiham Zerhouni
- J. Andrea McCartJMJ. Andrea McCart
- 1 June 2013
- journal article
- review article
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 19 (6) , 378-392
Abstract
No abstract availableKeywords
This publication has 103 references indexed in Scilit:
- Antitumor Efficacy of 34.5ENVE: A Transcriptionally Retargeted and “Vstat120”-expressing Oncolytic VirusMolecular Therapy, 2012
- Bevacizumab With Angiostatin-armed oHSV Increases Antiangiogenesis and Decreases Bevacizumab-induced Invasion in U87 GliomaMolecular Therapy, 2012
- Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in miceBritish Journal of Cancer, 2011
- Precise Scheduling of Chemotherapy Primes VEGF-producing Tumors for Successful Systemic Oncolytic VirotherapyMolecular Therapy, 2011
- Targeting Tumor Vasculature With an Oncolytic VirusMolecular Therapy, 2011
- The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting AgentsCancer Treatment Reviews, 2011
- VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapyGene Therapy, 2010
- Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumoursGene Therapy, 2009
- Intravascularly Administered RGD-Displaying Measles Viruses Bind to and Infect Neovessel Endothelial Cells In VivoMolecular Therapy, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009